Anxiety control in dental surgery

The efficacy of Alprazolam for Anxiety control in third molar extractions

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

REBEC

Registry ID

RBR-39gws45

Enrollment

Unknown

Registered

2024-08-20

Start date

2024-03-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Surgery Oral

Interventions

This is a clinical study, randomized, double-blind, interventional, split-mouth design, placebo-controlled, involving 18 adult individuals of both sexes, patients from the specialization center for or

D03.633.100.079.080.030

Eligibility

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers; both genders; aged between 18 and 40 years; requiring extraction of retained third molars in similar positions regarding the type of impaction

Exclusion criteria

Exclusion criteria: Patients under 18 years old or over 40 years old; patients with body weight below 50kg or above 90kg; patients who have used anti-inflammatory or analgesic drugs up to 1 week before the first dental intervention; patients with a history of contraindication to the use of benzodiazepines

Design outcomes

Primary

Measure	Time frame
It is expected that Alprazolam at a dosage of 1mg will be effective for anxiety control and operative comfort during third molar extractions compared to the placebo.	—

Secondary

Measure	Time frame
No secondary outcomes are expected.	—

Countries

Brazil

Contacts

Public ContactCamila Candido

Universidade Estadual de Campinas

camilaca@unicamp.br+55(11)971312599

Outcome results

None listed

Source: REBEC (via WHO ICTRP)